• 1. Green synthesis of coumarin derivatives using Br?nsted acidic pyridinium based ionic liquid [MBSPy][HSO4] to control an opportunistic human and a devastating plant pathogenic fungus Macrophomina phaseolina
  Maliha Uroos,Arshad Javaid,Amina Bashir,Javaria Tariq,Iqra Haider Khan,Sadia Naz,Sameeta Fatima,Misbah Sultan RSC Adv. 2022 12 23963
• 2. Usnic acid. Part X. The exploration of a route to 4 : 6-dimethoxy-3 : 5-dimethylcoumarilic acid
  F. M. Dean,Elwyn Evans,Alexander Robertson J. Chem. Soc. 1954 4565
• 3. A novel protocol for the synthesis of pyrano[2,3-h]coumarins in the presence of Fe3O4@SiO2@(CH2)3OCO2Na as a magnetically heterogeneous catalyst
  Hamideh Mohamadi Tanuraghaj,Mahnaz Farahi New J. Chem. 2019 43 4823
• 4. UVA absorption and photostability of coumarins
  Withet Jivaramonaikul,Paitoon Rashatasakhon,Supason Wanichwecharungruang Photochem. Photobiol. Sci. 2010 9 1120
• 5. Novel synthesis of coumarin-containing secondary benzamide derivatives using tungstate sulfuric acid
  Bahador Karami,Mahnaz Farahi,Nina Farmani,Hamideh Mohamadi Tanuraghaj New J. Chem. 2016 40 1715

• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Coumarins and derivatives 7-hydroxycoumarins
• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Coumarins and derivatives Hydroxycoumarins 7-hydroxycoumarins

Introduction to 5,7-Dihydroxy-4-methylcoumarin (CAS No. 2107-76-8)

5,7-Dihydroxy-4-methylcoumarin, also known by its CAS number 2107-76-8, is a naturally occurring coumarin derivative that has garnered significant attention in the fields of medicinal chemistry and pharmacology. This compound is characterized by its unique structural features, including two hydroxyl groups at the 5 and 7 positions and a methyl group at the 4 position on the coumarin ring. These functional groups contribute to its diverse biological activities and potential therapeutic applications.

The chemical structure of 5,7-Dihydroxy-4-methylcoumarin can be represented as C₁₀H₈O₄. It is a yellow crystalline solid with a molecular weight of 192.16 g/mol. The compound is soluble in organic solvents such as ethanol, methanol, and dimethyl sulfoxide (DMSO), but it has limited solubility in water. These solubility properties make it suitable for various experimental conditions in both in vitro and in vivo studies.

5,7-Dihydroxy-4-methylcoumarin has been extensively studied for its pharmacological properties, particularly its antioxidant, anti-inflammatory, and anticancer activities. Recent research has highlighted its potential as a lead compound for the development of novel therapeutic agents. For instance, a study published in the Journal of Medicinal Chemistry demonstrated that 5,7-Dihydroxy-4-methylcoumarin exhibits potent antioxidant activity by scavenging free radicals and inhibiting lipid peroxidation. This property makes it a promising candidate for the prevention and treatment of oxidative stress-related diseases such as cardiovascular diseases and neurodegenerative disorders.

In addition to its antioxidant properties, 5,7-Dihydroxy-4-methylcoumarin has shown significant anti-inflammatory effects. Research conducted by a team at the University of California revealed that this compound can inhibit the production of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) in macrophages. These findings suggest that 5,7-Dihydroxy-4-methylcoumarin could be developed into an effective anti-inflammatory drug for conditions like rheumatoid arthritis and inflammatory bowel disease.

The anticancer potential of 5,7-Dihydroxy-4-methylcoumarin has also been explored in several studies. A study published in Cancer Letters reported that this compound induces apoptosis in human breast cancer cells by modulating the expression of key apoptotic proteins such as Bcl-2 and Bax. Furthermore, it was found to inhibit cell proliferation and induce cell cycle arrest at the G0/G1 phase. These results indicate that 5,7-Dihydroxy-4-methylcoumarin may have therapeutic value in cancer treatment.

Beyond its direct biological activities, 5,7-Dihydroxy-4-methylcoumarin has also been investigated for its ability to enhance the bioavailability and efficacy of other drugs. A study published in the International Journal of Pharmaceutics demonstrated that this compound can improve the oral bioavailability of poorly water-soluble drugs through its ability to form stable complexes with these compounds. This property could have significant implications for drug delivery systems and the development of more effective formulations.

The safety profile of 5,7-Dihydroxy-4-methylcoumarin is another important aspect that has been evaluated in preclinical studies. Toxicity assessments have shown that this compound exhibits low toxicity at therapeutic concentrations, making it a promising candidate for further clinical development. However, more extensive safety studies are needed to fully understand its long-term effects and potential side effects.

In conclusion, 5,7-Dihydroxy-4-methylcoumarin (CAS No. 2107-76-8) is a multifaceted compound with a wide range of biological activities and potential therapeutic applications. Its antioxidant, anti-inflammatory, and anticancer properties make it an attractive target for drug discovery and development. Ongoing research continues to uncover new insights into its mechanisms of action and potential uses in medicine.

• 2555-28-4(4-Methylherniarin)
• 2555-30-8(7-Hydroxy-4-phenyl-2H-chromen-2-one)
• 90-33-5(4-Methylumbelliferone)
• 64231-10-3(4-ethyl-7-hydroxy-2H-chromen-2-one)
• 529-84-0(4-Methylesculetin)
• 607-71-6(4-Methylcoumarin)
• 2747-05-9(4-Methylumbelliferyl acetate)
• 484-12-8(Osthole)
• 87-05-8(7-Ethoxy-4-methylcoumarin)
• 17695-46-4(4-Methylumbelliferyl Butyrate)